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Background. Endovascular aneurysm repair has been criticised for high rates of technical failure and secondary
intervention. Second generation stent-grafts have been developed in an attempt to reduce these problems. The results of a UK
multi-centre experience with a second generation device (Zenith) are presented.
Methods. Data were collected retrospectively from five experienced UK vascular centres in patients undergoing
endovascular aneurysm repair with the Zenith stent-graft.
Results. A total of 269 patients underwent attempted aneurysm repair with the Zenith device. Median aneurysm diameter
was 65 (interquartile range 52–78) mm. There were no conversions to open repair. Peri-operative mortality was 4.1%
(11/269). On the initial post-operative scan, 94.1% of aneurysms were successfully excluded. During a median follow-up of
363 (interquartile range 154–720) days there were 19 secondary interventions and two aneurysm ruptures.
Conclusions. Second generation endovascular stent-graft designs such as the Zenith are associated with low rates of intra-
operative technical complications. Few secondary interventions have been necessary during follow-up; however, surveillance
is essential to ensure they continue to perform.
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Background
Endovascular repair of infra-renal abdominal aortic
aneurysms (EVAR) has been criticised for high rates of
technical failure and secondary intervention.1 In
addition there have been some cases of aneurysm
rupture.2 During a 6-year follow-up of the AneuRx
device aneurysm rupture occurred in 1.3% of patients
and in 4.3% of Chuter stent-grafts at 7 years.3,4
However, many of the complications were experi-
enced with first generation devices.
Lessons have been learned from the failures of the
early generation devices.4 Second generation endo-
vascular stent-grafts incorporate features intended to
prevent problems encountered with earlier designs.
Specifically they have been manufactured to facilitate
insertion, prevent endoleak and resist migration.
To examine whether these design changes have
resulted in improved outcome the results from a UK
multi-centre with a second-generation endovascular
stent-graft (Zenith) are reported.
Methods
A single investigator (JG) collected data indepen-
dently from the five participating centres. Each centre
comprised a team of surgeons and radiologists
experienced in endovascular aneurysm surgery (all
centres submit patients to the UK national randomised
EVAR trials and had experience with earlier gener-
ation stent-grafts). All Zenith grafts used in the centres
were included in the study. Patient selection and
follow-up were at the discretion of the surgeon/ra-
diologist in the participating centre. Grafts were
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planned with contrast-enhanced spiral CT and angio-
graphy was used selectively. Graft oversizing of 15%
was used and they were inserted either in theatre with
a C-arm image intensifier or in a radiology suite.
All patients underwent post-operative graft sur-
veillance, which included clinical and radiological
(either duplex ultrasonography or contrast enhanced
spiral computed tomography) assessment. The
majority of patients underwent radiological assess-
ment at discharge or within the first post-operative
month. (Other surgeons preferred to wait to perform
investigation especially where the completion angio-
gram was normal and post-operative course unevent-
ful in the hope that any type II endoleaks would have
spontaneously sealed.) Subsequent assessment inter-
vals varied but in general patients were assessed two
or three times in the first post-operative year and then
yearly thereafter (assuming no complications had been
identified).
Results
A total of 269 patients underwent attempted EVAR
with the Zenith endovascular stent-graft. Three
patients were treated with an early design of the
Zenith stent-graft in July 1996. The other patients
underwent repair from April 1998–November 2002.
Median age of patients was 74 (inter-quartile range
69–78) years and 241 (89.6%) were male. Twenty-one
patients were treated with acute symptomatic tender
aneurysms (one of which was ruptured). Patients had
a variety of co-morbidity. Thirty-seven (13.8%) with
diabetes mellitus, 109 (40.5%) had previous myocar-
dial infarction; 90 (33.4%) angina; 115 (42.8%) with
treated hypertension and 53 (19.7%) had chronic
obstructive airways disease. A total of 66 (24.5%)
were currently tobacco smokers. Patients were graded
using the American Society of Anaesthesiology (ASA)
guidelines. Patients were grade I, 0.4%; II, 29.2%; III,
57.9%; IV, 12% and V, 0.4%. A total of 70% of patients
were ASA grade III or higher.
The median aneurysm diameter was 65 (interquar-
tile range 52–78) mm with a proximal neck length of
28 (interquartile range 11–45) mm and neck diameter
of 24 (interquartile range 19–29) mm. A total of 249
bifurcated and 20 uniiliac grafts were inserted.
The median duration of operation for the whole
group was 150 (interquartile range 90–210) min and
recorded blood loss of 400 (interquartile range 150–
900) ml. There were no conversions to conventional
open repair. One patient required laparotomy and
placement of peri-aortic ligatures for the treatment of a
proximal type I endoleak. On this occasion the
endograft had been planned from a CT scan which
was 12 months out of date. The proximal neck had
dilated over this time and consequently the endograft
was undersized. Another patient required placement
of a covered stent for type III (modular limb
disconnection) endoleak. Both endoleaks were suc-
cessfully treated.
There was no significant rise in serum creatinine
following EVAR. Median pre-operative creatinine was
105 (interquartile range 67–127) mmol/dl, highest
peri-operative 112 (interquartile range 63 –
140) mmol/dl and creatinine at discharge was 103
(interquartile range 62–127).
Only 28 (10.4%) patients required admission to an
Intensive Care Unit and the peri-operative mortality
was 4.1% (11/269). The ASA grade of the 11 who died
were grade IV ðn ¼ 3Þ; grade III ðn ¼ 7Þ; grade II ðn ¼
1Þ: Six deaths occurred in the symptomatic group. The
median in-patient stay was six (interquartile range 3–
9) days.
Following EVAR 255 (95%) patients underwent
either duplex or CT. Patients not undergoing these
investigations were the 11 who died during the peri-
operative period and three who remained in-patients
at the time of data collection. On the initial post-
operative scan 240/255 (94.1%) aneurysms were
successfully excluded. Of the endoleaks only two
were attachment site (type I) endoleaks. The remaining
13 were type II (patent side-branch) endoleaks.
During an overall median follow-up of 363 (inter-
quartile range 154–720) days, a further 19 patients
developed an endoleak (Fig. 1). Only two of these were
type I endoleaks. One type I endoleak had probably
been present since the first post-operative scan but was
interpreted as type II endoleak on initial CT scan. No
type III endoleak occurred during the follow-up
period. All four type I endoleaks were managed
surgically. In contrast only three interventions were
undertaken out of a total of 30 type II endoleaks.
Fourteen of the type II endoleaks sealed spon-
taneously and 13 were observed. One aneurysm with
type II endoleak continued to expand. Whilst under-
going investigation the patient presented with a fatal
aneurysm rupture.
There were a total of 19 secondary interventions
during the follow-up period, the majority of which
Table 1. Secondary interventions following EVAR.
Secondary intervention Number ðn ¼ 21Þ
Local groin 3
Endovascular 10
Bypass/endarterectomy 4
Laparotomy 4
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were performed via the endovascular route (Table 1).
Only one endograft underwent caudal migration,
which occurred 24 months post-operatively. There
was no endoleak detected but the aneurysm started to
enlarge. The patient was successfully managed with a
proximal endovascular extension and the aneurysm
remains excluded.
A total of 28 patients died during follow-up (Fig.
2(a) and (b)). Only two of these were due to aneurysm
rupture (Table 2). Both were predictable events. One
patient is described above with a rupture secondary to
type II endoleak. Another patient died due to an
untreated proximal type I endoleak. An attempted
endovascular treatment of the endoleak failed and the
patient was deemed at prohibitively high risk from
medical co-morbidity to undergo conversion to open
repair.
Discussion
Early experiences with EVAR using first-generation
devices were associated with high rates of compli-
cations. Conversions to open repair reached 20% in
some series.5 Early devices were not subject to the
same stringent regulations. Only recently have these
been introduced because of significant problems
associated with new technology in medicine and in
particular in vascular surgery.6 Parallels can be drawn
with the introduction of new technology in general
surgery. Early experiences with laparoscopic chole-
cystectomy were associated with high rates of conver-
sion and bile duct injuries. In addition the first
randomised controlled trial was unable to demon-
strate any benefit compared with mini-laparotomy.7
The results of this study support the Australian
experience of EVAR using the same stent-graft.8 In this
series no patients required conversion to open repair.
The large EUROSTAR database demonstrated type
I endoleak, type III endoleak, migration and graft
kinking were the factors associated with aneurysm
rupture following EVAR.9 In this series there was a
low incidence of any of these complications during the
relatively short follow-up period.
In only one patient was caudal stent-graft migration
detected. This complication occurred with an early
device deployed in 1996 in which some of the barbs
broke. Since that time the design of the barbs of the
supra-renal uncovered stent-graft have been made
more robust and this complication has not occurred
again. Experimental evidence from cadaveric aortas
would suggest that this device requires a force 10
times that which was required to distract some of the
first generation designs (consequently when the barbs
were broken in one of the Zenith stent-grafts the
device migrated).10 In vitro analysis demonstrated the
force required to precipitate migration of this endo-
vascular stent-graft are two–three fold greater than
the forces which are generated in the aorta.
Fig. 1. Kaplan–Meier analysis of freedom from endoleak during follow-up.
Table 2. Cause of death in patients during follow-up.
Cause of death Number ðn ¼ 28Þ
AAA rupture 2
Thoracic aneurysm rupture 1
Myocardial infarction 5
Respiratory 3
Stroke 3
Renal failure 1
Malignancy 6
Unknown 7
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Concerns regarding the effect of trans-renal fixation
(with stainless steel wires) on renal function appear
unfounded.11,12 Indeed in this study we were unable to
demonstrate any significant rise in creatinine at
discharge in the whole group.
Early endovascular grafts were associated with
high rates of secondary intervention (up to 40% at 4
years).13 This paper suggests that secondary interven-
tions are still likely to be a feature of EVAR but may
occur with a reduced frequency. In this study
secondary interventions were only required in 7.5%
(19/255) of patients during the follow-up period. The
majority of these were performed by the less invasive
endovascular route.
Overall 30 (11.8%) patients developed type II
endoleak, comparable to reports by other authors.14
Patients with type II endoleak were not treated unless
there was evidence of aneurysm sac expansion (in-line
with international consensus opinion).15 One patient
in this series suffered aneurysm rupture secondary to
type II endoleak. This case has been reported
previously and emphasises the fact that type II
endoleaks are not always benign.16
Many lessons from the early devices have been
learned. Consequently EVAR with second generation
devices such as the Zenith are associated with low
rates of intra-operative technical complications. Simi-
larly few secondary interventions have been necessary
during follow-up. Improvements in early outcome
may be attributed to improved technology but the
importance of the learning curve must not be under-
estimated.17
Surveillance of endovascular stent-grafts remains
vital to ensure they continue to perform.
References
1 Collin J, Murie JA. Endovascular treatment of abdominal aortic
aneurysm: a failed experiment. Br J Surg 2001; 88: 1281–1282.
2 Walker S, Papavassiliou V, Fishwick G, Bell PR. Early rupture
of a partially treated abdominal aortic aneurysm: another
endovascular lesson. J Endovasc Ther 2002; 9: 587–589.
Fig. 2. (a) Life-table analysis of survival (all cause mortality). (b) Life-table analysis of freedom from aneurysm related death.
R. J. Hinchliffe et al.54
Eur J Vasc Endovasc Surg Vol 27, January 2004
3 Zarins CK. AneuRx Clinical Investigators. The US AneuRx
Clinical Trial: 6-year clinical update 2002. J Vasc Surg 2003; 37:
904–908.
4 Alric P, Hinchliffe RJ, Chuter TA et al. Lessons learned from
the long-term follow-up of a first generation stent-graft. J Vasc
Surg 2003; 37: 367–373.
5 Thompson MM, Sayers RD, Nasim A et al. Aortomonoiliac
endovascular grafting: difficult solutions to difficult aneurysms.
J Endovasc Surg 1997; 4: 174–181.
6 Beard JD. How can we introduce new technology safely and
effectively? Eur J Vasc Endovasc Surg 2001; 21: 3–5.
7 Majeed AW, Troy G, Nicholl JP et al. Randomised, prospective,
single-blind comparison of laparoscopic versus small-incision
cholecystectomy. Lancet 1996; 347: 989–994.
8 Lawrence-Brown M, Sieunarine K, Hartley D et al. The Perth
HLB bifurcated endoluminal graft: a review of the experience
and intermediate results. Cardiovasc Surg 1998; 6: 220–225.
9 Harris PL, Vallabhaneni SR, Desgranges P et al. Incidence
and risk factors of late rupture, conversion, and death after
endovascular repair of infrarenal aortic aneurysms: the EURO-
STAR experience. European collaborators on stent/graft tech-
niques for aortic aneurysm repair. J Vasc Surg 2000; 32: 739–749.
10 Resch T, Malina M, Lindblad B et al. The impact of stent design
on proximal stent-graft fixation in the abdominal aorta: an
experimental study. Eur J Vasc Endovasc Surg 2000; 20: 190–195.
11 Birch PC, Start RD, Whitbread T et al. The effects of crossing
porcine renal artery ostia with various endovascular stents. Eur J
Vasc Endovasc Surg 1999; 17: 185–190.
12 Macierewicz J, Walker SR, Vincent R et al. Vascular surgical
society of Great Britain and Ireland: perioperative renal function
following endovascular repair of abdominal aortic aneurysm
with suprarenal and infrarenal stents. Br J Surg 1999; 86: 696.
13 Laheij RJF, Buth J, Harris PL et al. Need for secondary
interventions after endovascular repair of abdominal aortic
aneurysms. Intermediate-term follow-up results of a European
collaborative registry (EUROSTAR). Br J Surg 2000; 87:
1666–1673.
14 Fairman RM, Carpenter JP, Baum RA et al. Potential impact of
therapeutic warfarin treatment on type II endoleaks and sac
shrinkage rates on midterm follow-up examination. J Vasc Surg
2002; 35: 679–685.
15 Veith FJ, Baum RA, Ohki T et al. Nature and significance of
endoleaks and endotension: summary of opinions expressed at
an international conference. J Vasc Surg 2002; 35: 1029–1035.
16 Hinchliffe RJ, Singh-Ranger R, Davidson IR, Hopkinson BR.
Rupture of an abdominal aortic aneurysm secondary to type II
endoleak (Lesson of the Month). Eur J Vasc Endovasc Surg 2001; 22:
563–565.
17 Lobato AC, Rodriguez-Lopez J, Diethrich EB. Learning curve
for endovascular abdominal aortic aneurysm repair: evaluation
of a 277 patient single-centre experience. J Endovasc Ther 2002; 9:
262–268.
Accepted 6 October 2003
A UK Multi-centre Experience with a Second-generation Endovascular Stent-graft 55
Eur J Vasc Endovasc Surg Vol 27, January 2004
